Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2025-01-28 Earnings Release
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Half Year Trading update
Earnings Release Classification · 1% confidence The document is titled 'Half Year Trading update for the six months ended 31 December 2024' and provides key financial highlights (revenue, cash position) and operational updates (clinical trials, MAA submission) for a six-month period. It explicitly states that the company is providing this update 'ahead of its Interim Results to be announced in March 2025'. This structure—a summary of interim performance released before the full, formal Interim Report—is characteristic of an Earnings Release (ER). It is not the comprehensive Interim Report itself (IR), nor is it a full Annual Report (10-K). The presence of the RNS Number and the closing boilerplate confirms it is a regulatory announcement, but the content is specifically an earnings/trading update. H1 2025
2025-01-28 English
PDMR Dealing and Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement released via RNS (RNS Number: 1856U) on January 22, 2025. The content details the issuance and cancellation of shares, specifically mentioning transactions by a Director/PDMR (Dr. Shaun Furlong) and the resulting Total Voting Rights calculation based on FCA DTR rules. This structure—announcing insider transactions (PDMR Dealing) and share capital changes—is characteristic of regulatory disclosures concerning insider dealings or capital structure updates. Since there is a specific category for 'Director's Dealing' (DIRS) which covers personal share transactions by directors, this is the most appropriate classification. It is not a general earnings release (ER), a full annual report (10-K), or a proxy statement (PSI).
2025-01-22 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is an RNS announcement from Allergy Therapeutics plc, dated January 15, 2025. The content explicitly details the 'Issue of 687,500,000 Warrants' related to a loan facility and includes a formal table titled 'Notification and public disclosure of transactions by Director/persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA")'. This structure, focusing on transactions by directors/insiders, directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific subject matter is insider trading disclosure, making DIRS the most accurate classification over the general RNS fallback.
2025-01-15 English
Exercise of Options and Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is clearly identified as an 'RNS Number' announcement from the London Stock Exchange. The content announces the application for admission to trading of new ordinary shares following an option exercise, and confirms the total voting rights. This type of official, brief regulatory update that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2024-12-19 English
Block Listing Interim Review
Regulatory Filings Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 4634Q' and contains standard boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a formal update titled 'Block Listing Interim Review' detailing the status of shares under an incentive plan over a specific period (Oct 1, 2023, to Dec 17, 2024). This type of formal, periodic regulatory update that doesn't fit into specific financial reporting categories (like 10-K, ER, or IR) is best classified as a general Regulatory Filing. Since RNS is the source and the content is a standard regulatory disclosure, RNS is the most appropriate code.
2024-12-17 English
Result of Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states 'Result of Annual General Meeting' and provides a detailed table showing the results of proxy votes for resolutions (1 through 16) presented at the '2024 Annual General Meeting ("AGM") held today'. This content directly corresponds to the announcement of voting outcomes following an AGM. The most specific category for this is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, DVA is more precise than AGM-R, which is defined as presentations and materials shared *during* the AGM.
2024-12-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.